QPS Holdings, LLC

QPS is a GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has rapidly expanded from a tiny bioanalysis shop to a full-service CRO with 1100+ employees in the US, Europe, India and Asia. Today, it offers expanded pharmaceutical contract R&D services with special expertise in Neuropharmacology, DMPK, Toxicology, Bioanalysis, Translational Medicine and all Phases of Clinical Development. QPS has CLIA-certified and GLP-compliant laboratories ready fast track your novel coronavirus and COVID-19 RT-qPCR/QPCR and Serological Assays, and vaccine or therapy development programs. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction and turnkey laboratories and facilities. For more information, visit www.qps.com or email [email protected].  For more information on Covid-19 related projects, visit www.qps.com/coronavirus or email [email protected].

• Website: https://www.qps.com
• Email: [email protected]
• Telephone: 1 512 350 2827
• Address:  Delaware Technology Park, 3 Innovation Way, Suite 240, Newark, DE 19711

 

 

 

 

 

 

 

How SARS COV2 Spreads Infection So Efficiently: Part 1 The Spike Protein

Clinical Trial Shows in vivo CRISPR CAS9 Therapy Effective Against Rare Disease

Could Giraffes Advance Human Genetic Research?

The SARS COV2 Jump From Bats To Humans And What It Tells Us

Sign up for QPS Blog Updates!

eBook: High-Resolution Mass Spectrometry

eBook: the bioanalytical challenges and considerations of immunogenicity

Bioanalysis Milestones

Gene Therapy Milestones

Spotlight: DMPK

Protein binding determination, QC and acceptance criteria: an interview with Simon Wong

Peek behind the paper: LC–TOF–MS methods to quantify siRNAs

Peek behind the paper: how ADA methodology informs SARS-CoV-2 assay development

Ask the Experts – hybrid LBA/LC–MS

Brexit or not, the drug research and development landscape has changed

Ask the Experts: outsourcing

Hybrid LC–MS assays reaching standards for regulatory filings

Expert advice to young scientists

QPS expands their translational medicine capabilities at flagship facility in Delaware

QPS White Paper – Three lessons to help accelerate pharmaceutical breakthroughs for CNS disorders

International Women’s Day: an interview with Manuela Prokesch

International Women’s Day: an interview with Birgit Hutter-Paier

International Women’s Day: an interview with Stacey Gottschall

Defining a Full-Service ADME Data Package

The 5S of Hybrid LC MS/MS Methods

Challenges in Regulated Quantitative LC-MS Bioanalysis

3 Attributes of a Great Bioanalysis CRO Partner

The Application of (LC)-ICP-MS in Drug Development

Ligand Binding or Mass Spectrometry That is the Question

Defining a full-service ADME data package: mass balance, quantitative whole body autoradiography (QWBA), metabolite profiling and metabolite identification

Panel discussion: developments in the oligonucleotide field

Panel discussion: FDA guidance, transitioning skills and future hopes for the bio lab

Business of bioanalysis: season two

The changing world of bioanalysis panel discussion

Business of bioanalysis: Bioanalysis Zone panel discussion

Bioanalysis Zone Panel Discussion

2020

QPS Missouri Projected to Pay $1 Million to Local Participants

QPS Awarded Two 2020 CRO Leadership Awards

QPS Continues to Expand UPLC-HRMS Quantitation Capabilities to Support Gene Therapy and Protein Drug Development

QPS Announces Novel Coronavirus/COVID-19 Testing Capability

QPS Assembles an Access Restricted Bioanalysis Lab to Support Drug Companies in the Fight Against Novel Coronavirus

QPS Forms Partnership with UMCG and G-CURE for Cardiovascular Drug Development

2021

QPS Supports COVID-19 Vaccine Development In Taiwan

QPS Awarded Five 2021 CRO Leadership Awards

QPS is currently planning to attend conferences in 2H 2021 and 1H 2022. Conference attendance will
vary based on COVID-19 restrictions and travel. As always, the safety of our staff and customers is our
first priority and adjustments will be made on an on-going basis. For more information about QPS at each
conference, please visit our page.

This is the list of conferences that QPS currently plans to attend. We hope to see you soon!

• TIDES USA 2021 (Boston)
• WRIB 2021 (Virtual)
• AAPS 2021 (Philadelphia)
• ASMS 2021 (Philadelphia)
• Outsourcing in Clinical Trials & Clinical Trial Supply Nordics 2021 (Copenhagen)
• EBF Open Symposium 2021 (Barcelona)
• Outsourcing in Clinical Trials DACH & Western Europe 2021 (Zurich)
• Outsourcing in Clinical Trials Israel 2022 (Tel Aviv)
• Outsourcing in Clinical Trials West Coast 2022 (Burlingame)

The Anitbody Drug Conjugate Challenge

Confidently Choose a CRO to Support Your IND Efforts

Human Mass Balance Studies

The Birth of RNAi 

Seeking Drug Approval Via The 505(b)(2) NDA Option

Biosimilar Drug Development